We also find that CMLD011580 can synergize with the DNA damaging agent, doxorubicin against Myr-Akt/Eμ-Myc lymphomas in vivo (Fig. 3b), despite the apparent inhibition of translation exerted by CMDL011580 in vivo being significantly shorter than (−)-CR-1-31-b (Fig. 3a). This evidence concerns the gene MYC and lymphoma.